Clinical trial · Interventional
Study of ENMD-2076 in Patients With Multiple Myeloma
A Phase 1 Study of ENMD-2076 in Patients With Relapsed or Refractory Multiple Myeloma
NCT00806065CI-TRIAL-00063678completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Safety, tolerability, maximum tolerated dose and clinical benefit of ENMD-2076 administered over a range of doses in patients with relapsed or refractory multiple myeloma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ENMD-2076 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- ENMD-2076
- description
- Oral capsules, once daily in 28-day cycles
- interventionNames
- Drug: ENMD-2076
Primary outcomes (1)
- measure
- Maximum tolerated dose of ENMD-2076
- timeFrame
- Within first 35 days
Secondary outcomes (2)
- measure
- Correlative studies of activity
- timeFrame
- throughout the study period
- measure
- Clinical Benefit
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Major Inclusion Criteria: 1. Histological evidence of MM and evidence of relapse or refractory disease. Patients with non secretory myeloma or plasmacytoma only will be excluded. 2. Patients must have failed thalidomide, lenalidomide, or velcade or be intolerant or ineligible to receive these agents. 3. Age ≥18 years. 4. ECOG performance status 0-2. 5. Patients must have adequate organ and marrow function Major Exclusion Criteria: 1. Prior cytotoxic chemotherapy or investigational agent within 28 days or autologous stem cell transplant within 6 months of receiving study drug ENMD-2076. 2. Prior radiation therapy to \> 25% of bone marrow forming bones (i.e., pelvis). 3. Concomitant corticosteroid therapy in doses greater than 10 mg daily of prednisone (or equivalent) if given for management of co-morbid conditions. 4. Have unstable angina pectoris or recent myocardial infarction (within 6 months. 5. Have uncontrolled hypertension or congestive heart failure.
References
Publications (0)
Data not yet available
No reference posted for this study.